Merck & Company Inc Cash Flow Conversion Efficiency
Merck & Company Inc cash flow conversion efficiency. Based on the latest financial reports, Merck & Company Inc (MRK) has a cash flow conversion efficiency ratio of 0.128x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($5.37 Billion) by net assets ($41.98 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Merck & Company Inc (1989–2025)
Cash flow conversion efficiency of Merck & Company Inc from 1989 to 2025. This chart illustrates how Merck & Company Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Merck & Company Inc (MRK) share price today for real-time trading data and today's change.
Merck & Company Inc Cash Flow Conversion Ratio Explained
Merck & Company Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Merck & Company Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Merck & Company Inc ranked by their cash flow conversion efficiency. Also see how much is Merck & Company Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Intel Corporation
NASDAQ:INTC
|
0.068x |
|
HSBC Holdings plc
MX:HBCN
|
N/A |
|
Novartis AG
MX:NVSN
|
0.094x |
|
Palantir Technologies Inc. Class A Common Stock
NYSE:PLTR
|
0.056x |
|
Cisco Systems Inc
NASDAQ:CSCO
|
0.038x |
|
Applied Materials Inc
NASDAQ:AMAT
|
0.119x |
|
Philip Morris International Inc
NYSE:PM
|
-0.825x |
|
Morgan Stanley
SA:MSBR34
|
-0.030x |
Annual Cash Flow Conversion Efficiency for Merck & Company Inc (1989–2025)
The table below shows the annual cash flow conversion efficiency of Merck & Company Inc from 1989 to 2025. Review MRK free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $52.66 Billion | $16.47 Billion | 0.313x | -32.44% |
| 2024-12-31 | $46.37 Billion | $21.47 Billion | 0.463x | +33.96% |
| 2023-12-31 | $37.63 Billion | $13.01 Billion | 0.346x | -16.64% |
| 2022-12-31 | $46.06 Billion | $19.09 Billion | 0.415x | +12.42% |
| 2021-12-31 | $38.26 Billion | $14.11 Billion | 0.369x | -8.62% |
| 2020-12-31 | $25.40 Billion | $10.25 Billion | 0.404x | -21.92% |
| 2019-12-31 | $26.00 Billion | $13.44 Billion | 0.517x | +27.22% |
| 2018-12-31 | $26.88 Billion | $10.92 Billion | 0.406x | +117.86% |
| 2017-12-31 | $34.57 Billion | $6.45 Billion | 0.186x | -27.55% |
| 2016-12-31 | $40.31 Billion | $10.38 Billion | 0.257x | -7.22% |
| 2015-12-31 | $44.77 Billion | $12.42 Billion | 0.277x | +72.23% |
| 2014-12-31 | $48.79 Billion | $7.86 Billion | 0.161x | -27.67% |
| 2013-12-31 | $52.33 Billion | $11.65 Billion | 0.223x | +23.26% |
| 2012-12-31 | $55.46 Billion | $10.02 Billion | 0.181x | -16.91% |
| 2011-12-31 | $56.94 Billion | $12.38 Billion | 0.217x | +14.15% |
| 2010-12-31 | $56.80 Billion | $10.82 Billion | 0.191x | +245.33% |
| 2009-12-31 | $61.48 Billion | $3.39 Billion | 0.055x | -82.23% |
| 2008-12-31 | $21.17 Billion | $6.57 Billion | 0.310x | -8.66% |
| 2007-12-31 | $20.59 Billion | $7.00 Billion | 0.340x | +0.32% |
| 2006-12-31 | $19.97 Billion | $6.77 Billion | 0.339x | -9.22% |
| 2005-12-31 | $20.38 Billion | $7.61 Billion | 0.373x | -16.46% |
| 2004-12-31 | $19.70 Billion | $8.80 Billion | 0.447x | -11.70% |
| 2003-12-31 | $19.49 Billion | $9.86 Billion | 0.506x | +22.82% |
| 2002-12-31 | $23.13 Billion | $9.53 Billion | 0.412x | -5.23% |
| 2001-12-31 | $20.89 Billion | $9.08 Billion | 0.435x | +12.27% |
| 2000-12-31 | $19.85 Billion | $7.69 Billion | 0.387x | +5.49% |
| 1999-12-31 | $16.70 Billion | $6.13 Billion | 0.367x | +13.71% |
| 1998-12-31 | $16.51 Billion | $5.33 Billion | 0.323x | -29.68% |
| 1997-12-31 | $13.76 Billion | $6.32 Billion | 0.459x | +20.77% |
| 1996-12-31 | $14.28 Billion | $5.43 Billion | 0.380x | +81.01% |
| 1995-12-31 | $14.02 Billion | $2.94 Billion | 0.210x | -37.37% |
| 1994-12-31 | $12.35 Billion | $4.14 Billion | 0.335x | +22.80% |
| 1993-12-31 | $11.17 Billion | $3.05 Billion | 0.273x | -38.63% |
| 1992-12-31 | $5.63 Billion | $2.50 Billion | 0.445x | +0.71% |
| 1991-12-31 | $5.51 Billion | $2.43 Billion | 0.442x | -5.81% |
| 1990-12-31 | $4.38 Billion | $2.06 Billion | 0.469x | +36.89% |
| 1989-12-31 | $4.03 Billion | $1.38 Billion | 0.343x | -- |
About Merck & Company Inc
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, a… Read more